Predict your next investment

Corporation
HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year

1984

Stage

IPO | IPO

Total Raised

$19.2M

Date of IPO

6/28/1991

About Curative Technologies

Developer of therapeutics utilizing naturally occurring human growth factors. The initial indication for this technology is in treating chronic non-healing wounds. The product, called Procuren, is produced from a patient's own blood. Procuren, an autologous platelet derived wound healing formula, is a naturally occurring complex mixture of growth factors that promotes the growth of skin, soft tissue, and blood vessels. In November 1990, the company completed phase 2 clinical trials of a second would healing product and is currently seeking authorization for the FDA to begin phase 3 trials. Chronic non-healing wounds are common in patients with diabetes and venous stasis disease, as well as in patients who are immobilized and afflicted with pressure sores.

Curative Technologies Headquarter Location

14 Research Way

East Setauket, New York, 11733,

United States

(516)689-7000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Curative Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Curative Technologies is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,734 items

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.